WALTHAM, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Sartorius and Repligen Corporation (NASDAQ:RGEN) today announced the launch of an integrated bioreactor system that incorporates Repligen XCell® ATF ...

In recent years, fed-batch biomanufacturing has begun giving way to continuous manufacturing processes, as developers face pressure to balance affordability with high manufacturing quality. Although ...

Sartorius Stedim Biotech (SSB) said today it will integrate Repligen’s XCell™ ATF cell retention control technology into SSB’s BIOSTAT® STR large-scale single-use bioreactors to create novel perfusion ...

Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, and Repligen Corporation, a global life sciences company focused on bioprocessing technologies, ...

Bioreactor and cell retention technology integration features a single direct control interface to simplify intensified seed train implementation Customers experience optimized facility equipment ...